In addition, the accuracy of MELD scores in predicting the natural history of patients with decompensated HBV cirrhosis has not been prospectively determined. Because the natural history of ...

Patients with NASH display decreased mitochondrial ... or hepatic encephalopathy is indicative of progression to decompensated cirrhosis. Steatosis is diffuse in most patients, but can ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson under a compassionate ...

Decompensated liver cirrhosis, an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into ...

Another outcomes study is also ongoing, which is evaluating Rezdiffra versus placebo for progression to liver decompensation events in patients with well-compensated NASH cirrhosis. Several other ...

Acute kidney injury (AKI) is estimated to occur in up to 50% of patients with liver cirrhosis and is associated with increased morbidity and a high risk of short-term and long-term mortality.1 ...

These features make lamivudine a more appropriate treatment compared with IFN for patients with decompensated HBV cirrhosis. The recommended dose of lamivudine is 100 mg daily. Because lamivudine ...

Decompensated liver cirrhosis, an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into ...